Clinical Trials Logo
  1. Home
  2. Covid19
  3. NCT04613986

Therapeutic Plasma Exchange as an Adjunctive Strategy to Treat Coagulopathy and Inflammation in Severe Covid-19 — PExCoV  

Severe Covid-19 Clinical Trial

Official title:
Randomized, Prospective, Open-label, Controlled Parallel-group Trial Investigating the Efficacy of Therapeutic Plasma Exchange as an Adjunctive Strategy to Treat the Systemic Inflammatory Response Against SARS-CoV2 and the Associated Coagulopathy

Clinical Trial Summary

Randomized controlled trial to analyse adjuvant therapeutic plasma exchange (TPE) in severe Covid-19 associated coagulopathy and systemic inflammation compared to current standard of care (SOC). A total of three TPEs (d1, 3, 5) will be performed in the intervention group. Primary endpoint is the reversibility of relative ADAMTS13 deficiency (indicated by the change in ADAMTS13 / VWF:Ag ratio from day 1 to 7).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04613986
Study type Interventional
Source University of Zurich
Contact
Status Not yet recruiting
Phase N/A
Start date June 2021
Completion date July 2022
View Details
See also
  Status Clinical Trial Phase
Completed NCT05175833 - Oral Probiotics and Secondary Bacterial Pneumonia in Severe COVID-19 Phase 2
Recruiting NCT05256511 - COVID-19 and VA-LRTI: Second Versus First Wave of the Pandemic
Completed NCT04866082 - Corticosteroids in Severe COVID-19 (ASAP-ESICM/ESAIC Study)
Active, not recruiting NCT04918901 - Comparative Analysis of Clinical Parameters and Radiographic Changes of Severe COVID-19
Recruiting NCT05233605 - Impact of Post-ARDS Covid-19 Sedation on Persistent Neuroinflammation
Recruiting NCT05447013 - Generation of SARS-CoV-2-specific T Lymphocytes From Recovered Donors and Administration to High-risk COVID-19 Patients Phase 1/Phase 2
Completed NCT04733833 - A Study to Evaluate the Efficacy and Safety of VB-201 in Patients With COVID-19 Phase 2
Recruiting NCT04712344 - Assessment of Efficacy and Safety of Therapy With COVID-19 Convalescent Plasma in Subjects With Severe COVID-19 (IPCO) Phase 2
Terminated NCT04713176 - Efficacy and Safety of DWJ1248 With Remdesivir in Severe COVID-19 Patients Phase 3
Recruiting NCT04648410 - Corticosteroids in Severe COVID-19(ASAP-C Study)
Enrolling by invitation NCT06235866 - Risk Identification of Long-term Complications
Recruiting NCT05254990 - Reparixin add-on Therapy to Std Care to Limit Progression in Pts With COVID19 & Other Community Acquired Pneumonia Phase 3
Completed NCT05596617 - Safety and Efficacy of Medications COVID-19 N/A